ERVW-1 and infection: Although the enthusiasm for this type of antibody function was mostly evoked by the RV144 trial, the evidence also exists from vaccination strategies with Env immunogens in non-human primates (NHP) that link FcR effector functions of antibodies with post-infection control of viremia and/or blocking HIV-1 acquisition, often in the absence of neutralization (40–45), reviewed in (27).